The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
In a study involving 250 military veterans, researchers have reported identifying and testing gene expression biomarkers whose levels rise with human stress.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The assay uses a genomic DNA signature called the metastatic potential score derived from copy number alteration analysis of specific regions of the genome.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
